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Abstract Treatment of bovine heart ubiquinol-cytochrome c oxidoreductase (complex III, bc, complex) with ethoxyformic anhydride (EFA) inhibits 
electron transfer between cytochromes b and c, wagi et al., Biochemistry 21(1982) 4777-47823. This paper shows that EFA alters the EPR lineshape 
of the Rieske iron-sulfur cluster in complex III and in the isolated Rieske protein without a significant decrease of spin concentration. The effect 
of EFA on the Rieske iron-sulfur cluster is competitive with that of Q, site inhibitors, such as stigmatellin, and is completely reversed by 
hydroxylamine. These results are consistent with the possible thoxyformylation by EFA of histidine ligands of the Rieske iron-sulfur cluster at the 
non-iron binding imidazole nitrogens. 
Key worcis: Ethoxyformic anhydride’; Rieske iron-sulfur cluster; EPR spectra; Bovine ubiquinol-cytochrome c oxidoreductase; 
bc, complex; Complex III 
1. Introduction 
Quinol-cytochrome c (c2 or plastocyanin) oxidoreductases 
from mitochondria, chloroplasts, and photosynthetic or 
non-photosynthetic bacteria contain three redox proteins, a 
bis-heme cytochrome b, cytochrome c1 (or cytochrome f in 
chloroplasts), and a binuclear iron-sulfur protein [1,2]. This 
iron- sulfur protein, generally referred to as the Rieske iron- 
sulfur protein, differs from typical ferredoxin-type iron-sulfur 
proteins in the following respects:, (i) the Rieske iron-sulfur 
cluster is ligated by two histidine and two cysteine residues 
[3-71, (ii) it shows a unique EPR spectrum with average g value 
of 1.91 [1,2], and (iii) its redox midpoint potential is higher than 
+150 mV (see [l] and references therein). 
According to the modified Q-cycle hypothesis [2,8,9], two 
separate quinone reaction sites, Q, and Qi, are present on oppo- 
site sides of the membrane [1 , 10,111, and an electrogenic trans- 
membraneous electron transfer occurs between these two sites 
[12,13]. At the Q, site, two electrons from QH, are split; the tist 
electron reduces the Rieske iron-sulfur cluster, while the sec- 
ond electron cycles back via cytochrome b, (low potential 6) 
and b, (high potential b) to reduce Q at the Qi site [1,8,9]. The 
reduced Rieske iron-sulfur cluster is oxidized by the c-type 
cytochromes. 
The inhibitors of the enzyme (hereafter eferred to as com- 
plex III or bc, complex) are divided into two groups depending 
on their assigned reaction site near the Qi or the Q, site. Exam- 
ples of the former are antimycin, HQNO (2-n-heptyl4-hy- 
droxyquinoline-N-oxide) and diuron, and examples of the latter 
are myxothiazol, mucidin, stigmatellin and UHDBT (undecyl- 
hydroxydioxobenzothiazole) [ 1,141. Phenomenologically, how- 
ever, all of these reagents inhibit the oxidation of the b and the 
reduction of the c cytochromes in steady state kinetic analyses. 
*Corresponding author. 
‘Ethoxyformic anhydride is also referecl to as diethylpyrccarbcnate. 
Another reagent hat has the same effect on bovine complex 
III is ethoxyformic anhydride (EFA), which is capable of etho- 
xyformylating nucleophilic amino acid residues of proteins, 
including the imidazole nitrogens of histidyl residues [151. Yagi 
et al. [16] showed that the inhibitory modification of complex 
III by EFA did not alter the spectra of cytochromes b and ci, 
was complementary to the inhibition by antimycin A, resulted 
in the development of a peak at 238 mu, and was readily 
reversed by addition of hydroxylamine. While it was recognized 
that the peak at 238 nm and the ready reversibility by hydrox- 
ylamine are characteristic of ethoxyformylation of histidyl res- 
idues at one imidazole nitrogen, the site of EFA modification 
was not identified. This paper shows that EFA treatment of 
bovine complex III results in modification of the Rieske iron- 
sulfur protein, and the data suggest hat ethoxyformylation of 
complex III or the isolated bovine Rieske protein involves the 
histidine ligands of the iron-sulfur cluster. 
2. Materials and methods 
Bovine heart complex III was prepared as described in [17]. The 
Rieske iron-sulfur protein was isolated from bovine heart cytcchrome 
bc, complex as detailed in Ref [18]. The EFA treatment method is 
described in the figure legends, and follows the procedure reported in 
[16]. EPR spectra were recorded as described in [ll]. 
3. Results 
The effect of EFA on the EPR spectrum of the Rieske cluster 
in bovine heart complex III is shown in Fig. 1. The Rieske 
cluster reduced by Q2HZ (reduced ubiquinone-2) exhibits an 
EPR spectrum with g,,, = 1.76, 1.90, 2.023 (Fig. 1A). Upon 
treatment with EFA (Fig. lB), the Rieske lineshape became less 
rhombic, with the g, and g, shifting to 1.80 and 2.017, respec- 
tively, and with considerable broadening of the g, signal. These 
changes could be reversed by incubating the EFA-treated com- 
plex with hydroxylamine (Fig. lC), as a result of which the 
spectral features returned essentially to that in Fig. 1A. The 
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Fig. 1. Effect of ethoxyfotmic anhydride (EFA) on the EPR signature 
of the Rieske iron-sulfur cluster and the reversal of this effect by 
hydroxylamine. (A) 41 ,uM complex III was reduced with 1 mM ubiq- 
uinol-2. (B) 94.3 ,uM complex III was incubated with 7.6 mM EFA at 
1T for 10 min, then diluted to 41 ,uM and reduced as in (A). (C) EFA 
treated complex III (94.3 PM) was treated with 30 mM hydroxylamine 
for 30 min. at 0°C before dilution and reduction as in (B). EPR condi- 
tions: microwave power, 1 mW, modulation amplitude, 1 x lo-’ tesla; 
time constant, 0.128 s; sample temperature, 15 IL 
total spin concentration of the Rieske cluster in Fig. 1B did not 
show a significant decrease from that of Fig. lA, indicating that 
EFA does not modify the J-nitrogens of the two histidine imi- 
dazoles, which directly coordinate an iron of the Rieske iron- 
sulfur cluster [19]. The ready reversibility of this modification 
by hydroxylamine is consistent with the possibility that EFA 
ethoxyformylates one or both of these imidazole groups at their 
e-nitrogen(s). However, this conclusion does not preclude the 
possibility that the effect on the Rieske cluster lineshape origi- 
nates from EFA modification of histidine residues not directly 
involved in cluster formation. 
Fig. 2, shows the effect of EFA on the binding of various 
inhibitors to complex III. Fig. 2A presents the spectrum of the 
Rieske cluster in the EFA-treated bc, complex. In this case the 
g,,,, values are 1.80, 1.90, and 2.015. Subsequent antimycin 
treatment did not give rise to any alteration of the Rieske 
spectrum of the EFA-treated complex (Fig. 3B), as is expected 
for a Qi site inhibitor. Likewise, myxothiazol, which is known 
to bind to the cytochrome b domain of the Q, site [ 1,141 caused 
no spectral alteration of the Rieske cluster (not shown). Stig- 
matellin is known to exert a strong effect on both the lineshape 
and the redox midpoint potential of the Rieske cluster, as well 
as to induce a large spectral shift of cytochrome b, [20]. How- 
ever, when stigmatellin was added to the EFA-treated complex, 
the spectrum of the Rieske cluster again remained unaltered as 
in the case of antimycin treatment (Fig. 2C). For comparison, 
Fig. 2D shows the effect of stigmatellin on the Rieske lineshape 
when it was added to the bc, complex not pretreated with EFA. 
In this case a much sharper EPR lineshape with g,,,, = 1.79, 
1.88, 2.021 is seen, which is the specific signature of the effect 
of stigmatellin on the Rieske cluster (Fig. 2D). Similarly, no 
spectral alteration was observed with UHDBT (data not pre- 
sented). These results suggested that modification of the Rieske 
2.015 
Fig. 2. Pretreatment of complex III with EFA prevents the effect of 
stiamatellin on the EPR line shane of the Rieske iron-sulfur cluster. 
(Aj EFA treated complex III, same as in Fig. 1B. (B) Sample A was 
treated with 12.5 PM antimycin. (C) Sample A was treated with 125 PM 
stigmatellin. (D) EFA untreated complex III was reduced with 2.5 mM 
ascorbate, then treated with 125 PM stigmatellin. EPR conditions were 
the same as in Fig. 1. 
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Fig. 3. Effect of EFA on the EPR spectral features of the Rieske 
iron-sulfur cluster after pretreatment of complex III with various inhib- 
itors. The inhibitors shown were added to complex III (26 mg protein/ 
ml) at the final concentration of 125 ,uM. Subsequently EFA was added 
to a tinal concentration of 7.8 mM and incubated at 0°C for 10 min. 
After incubation, the Rieske cluster was reduced with ferrocytochrome 
cat the final concentration of 1.33 mM: A., antimycin; B., myxothiaxol; 
C., UHDBT, D., stigmatellin. EPR conditions were the same as in 
Fig. 1. 
iron-sulfur protein by EFA prevents stigmatellin and UHDBT 
from inducing changes in the Rieske lineshape, and are consis- 
tent with the possibility that EFA reacts directly with the 
Rieske cluster. 
Fig. 3 shows the effect of EFA after pretreatment of the bc, 
complex with various inhibitors. When antimycin was added 
prior to EFA (Fig. 3A), the lineshape of the Rieske iron-sulfur 
cluster was essentially the same as that effected by EFA alone 
(see Fig. 2A). A similar spectrum, with only a slight broadening 
of the g, lineshape, was obtained when myxothiazol was added 
prior to EFA. On the other hand, when complex III was pre- 
treated with UHDBT, which is a weak inhibitor of the Rieske 
domain of the Q, site, prior to addition of EFA, then the 
resulting spectrum appeared to be composed of contributions 
from two iron-sulfur species, one species being the EFA mod- 
ified type as indicated by peaks at g, z = 1.81 and 2.015 (Fig. 
3C), the other species being the remaining UHDBT bound form 
as suggested by the peaks at g,,= = 1.79 and 2.03. However, 
when the stigmatellin effect was examined, the major species 
appeared to be the stigmatellin-bound form, with g,,, = 1.79, 
1.88,2.023, plus only a small contribution from the EFA mod- 
ified species as suggested by the small shoulder to the left of the 
g = 1.88 peak (Fig. 3D). Competitive binding studies of various 
Q, site inhibitors have shown that stigmatellin has a much 
stronger affinity for the complex than UHDBT [14]. Therefore, 
it appears from the results in Fig. 3 that the ability of an 
inhibitor to prevent the modification of the Rieske lineshape by 
EFA correlates with its binding affinity. In previous studies of 
site specific inhibition, it was shown that those compounds 
which induced a lineshape change in the Rieske cluster of bo- 
vine heart bc, complex also altered its midpoint redox potential 
[21]. We attempted to investigate this possibility in EFA-treated 





Fig. 4. Effect of stigmatellin and EFA on the EPR spectrum of the 
isolated Rieske iron-sulfur protein. (A) 27 PM isolated Rieske iron- 
sulfur protein in 50 mM 3-(N-Morpholino)propanesulfuric acid 
(MOPS) @H 7.2) was reduced with 5 mM dithionite. (B) Sample A 
treated with 130 PM stigmatellin. (C) Sample A incubated with 7.6 mM 
EFA form 10 min on ice. 
106 Z Ohnishi et al. IFEBS Letters 353 (1994) 103-107 
reduced with sodium dithionite in the presence of redox medi- 
ators, the effects of EFA were readily reversed. Consequently, 
we were unable to measure any shift in the redox midpoint 
potential that might be caused by EFA treatment. It has been 
reported that EFA inhibits the electron transfer activity of 
complex III more strongly in its reduced state than in its oxi- 
dized state [16]. Therefore, it is possible that EFA modification 
results in a positive Em shift of the Rieske iron-sulfur cluster, 
similar to that produced by stigmatellin. 
In order to further pinpoint the effect of EFA on the Rieske 
iron-sulfur protein itself, we have examined the effect of this 
compound on isolated bovine heart Rieske iron-sulfur protein 
(Fig. 4). Isolated Rieske iron-sulfur protein [I81 reduced with 
dithionite exhibits an EPR spectrum with g,,, = 1.77, 1.89, 
2.026 (Fig. 4A). Stigmatellin does not induce any spectral ine- 
shape alteration in the isolated Rieske iron-sulfur protein (Fig. 
4B). However, upon treatment of the isolated Rieske protein 
with EFA, the EPR lineshape of the dithionite-reduced iron- 
sulfur cluster changed to g,,, = 1.80, 1.90, 2.010 (Fig. 4C), 
which is similar to the spectral change observed with the Rieske 
iron-sulfur protein localized within the bc, complex. 
4. Discussion 
It has been shown in this study that EFA treatment of bovine 
complex III or the isolated Rieske iron-sulfur protein results 
in a specific lineshape alteration of the Rieske iron-sulfur clus- 
ter, which can be reversed by subsequent reatment with hy- 
droxylamine. These data are consistent with the interpretation 
that EFA ethoxyformylates the non-iron binding &-nitrogen(s) 
of the histidine ligands of the Rieske iron-sulfur cluster (see 
Fig. 5). Lorusso et al. [22] have also observed an effect of EFA 
on the EPR g, feature of the Rieske iron-sulfur cluster (their 
data was not shown). They have concluded that the subtle 
spectral change of the Rieske cluster in EFA-treated prepara- 
tions is caused by conformational changes transmitted via the 
EFA-modified core protein II of the bc, complex. However, it 
is clear from our results that the EPR lineshape changes of the 
iron-sulfur cluster are the consequence of the direct modifica- 
tion of the Rieske iron-sulfur protein by EFA. 
We have shown that in complex III stigmatellin and 
UHDBT, but not myxothiazol and antimycin, compete with 




Fig. 5. A possible model of the Rieske iron-sulfur cluster ethoxyfor- 
mylated at the imidaxole nitrogens of the histidyl ligands. 
sulfur cluster. However, when the isolated Rieske protein was 
used, stigmatellin had no effect, whereas the effect of EFA was 
essentially the same. Brandt et al. 1231 have demonstrated that 
once the Rieske protein is completely deleted from the bc, 
complex, stigmatellin loses its tight binding capacity observed 
with intact bc, complex. These results together with our data 
suggest hat the stigmatellin binding site covers both the Rieske 
and the cytochrome b domains of the Q, pocket. 
Based on quantitative analysis of electron transfer kinetics, 
quinone occupancy at the Q, site, and the redox state of Q in 
Rhodobacter capsulatus wild-type and mutant chromatophores, 
Dutton and his colleagues [24,25] have proposed that the 
Rieske histidine-ligands may also function as direct hydrogen- 
bond donors to quinone and/or quinol at the Q, site, in a 
manner analogous to the QA and QB sites in the bacterial pho- 
tosynthetic reaction center of which high-resolution structural 
information is available [26,27]. It would be of interest o inves- 
tigate this point by quantitative analysis of EFA modification 
of the Rieske iron-sulfur protein in the Rb. capsulatus complex 
III, using both EPR and ENDOR analysis [4]. Bovine heart 
Rieske iron-sulfur protein contains 6 histidines; 3 non-con- 
served histidines may be located in the vicinity of the Rieske 
iron-sulfur cluster [28]. Rb. capsulatus Rieske iron-sulfur pro- 
tein contains five histidines; one is very close to the two ligand- 
histidines near the C-terminus and the remaining two histidines 
are located in the hydrophobic N-terminal region [6]. Mutants 
of Rb. capsulatus are available, in which the former histidine is 
replaced with alanine or serine. These mutants have wild-type 
properties [6]. EFA modification of the Rieske protein isolated 
from one of these mutants should allow a quantitative analysis 
of the EFA-modified histidine residues that alter the Rieske 
cluster spectrum. 
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